The invention relates to a device (10; 10a;10b; 10c; 50) for checking pharmaceutical products (1), in particular hard gelatin capsules, by means of at least one radiation source (30; 60) preferably embodied as an X-ray source, and a conveying device which conveys the products (1) in a clocked manner in a radiation area (31) of the radiation source (30; 60). The radiation emitted by the radiation source (30; 60) penetrating the products (1) preferably perpendicular to the longitudinal axes thereof (2), and the radiation is captured on the side of the products (1) opposite the radiation source (30) by means of at least one sensor element (35) which is coupled to an evaluation device (36). The invention is characterized in that the conveyor device is embodied as a conveyor wheel (15; 15a; 51) which can rotate in a stepped manner about an axis (12; 52), and the products (1) are arranged, while being conveyed in the radiation area (31), in receiving areas (28; 37; 56) of the conveyor wheel (15; 5a; 51).

A pharmacy bottle system includes a bottle and a ring. The bottle is formed as a single piece of molded plastic material and includes a body and a neck. The body defines an interior cavity. The interior cavity extends from a first end to a second end of the interior cavity. The body includes a spine portion covering the first end of the interior cavity. The spine portion defines a spine width measured from a front to a back of spine portion. The neck extends from the second end of the interior cavity and has an opening therethrough providing access to the interior cavity. The ring is secured about the neck of the bottle. The ring defines a ring width measured between a front and a back of the ring. The ring width is larger than the spine width. The neck extends above a top surface of the ring.

A storage case (100) for storing a pharmaceutical syringe unit (4) that is mounted to a pharmaceutical administering device (8) comprises a base body (1) that is open at its upper face, and a cover (2) for covering the opening in the base body (1). The base body (1) has in its interior a concave portion (5) that holds the cylindrical pharmaceutical syringe unit (4). The concave portion (5) has holders (6) that hold two ends of the pharmaceutical syringe unit (4), and a center concave portion (7) for attaching and removing the pharmaceutical syringe unit (4) and being provided in a position that corresponds to the main body portion of a stored pharmaceutical syringe unit (4). The center concave portion (7) further has a bottom part positioned lower than the holders (6), and is formed such that the pharmaceutical administering device (8) can be disposed in an upright position.

A semi-automated system suitable for use in a hospital setting for filling patient-specific liquid prescriptions to be administered by oral syringes on a just-in-time basis. The system enables hospital pharmacists to simplify and streamline their task, increasing the number of prescriptions that can be filled in a day, improving patient safety and care by minimizing medication errors and the consequences that ensue.

The present invention relates to means and methods for producing crystals or crystalline substances. In particular, crystals or crystalline substances which are useful as pharmaceutical ingredients can be manufactured.

Mineral, cosmetic, pharmaceutical, agricultural, nutraceutical, and other compositions are produced using a mineral composition containing minimal concentrations of cadmium, lead, arsenic, and mercury and containing relatively high concentrations of micro and macro mineral elements, of rare earth elements, of calcium, and of silica. The mineral concentrations are produced by processing naturally occurring clay soil to concentrate mineral elements naturally occurring in the soil.

Long Island’s pharmaceutical industry now makes up one of the region’s largest employers of manufacturing jobs. That’s according to a report released this week by the Suffolk County Industrial Development Agency.

Recruitment experts at Manpower, KellyOCG, PeopleStrong, and Xpheno predict that even as many sectors see widespread layoffs, there will be a silver lining in sectors like edtech, ecommerce/internet, transport and logistics, as well as pharma that continue to hire.

Recruitment experts at Manpower, KellyOCG, PeopleStrong, and Xpheno predict that even as many sectors see widespread layoffs, there will be a silver lining in sectors like edtech, ecommerce/internet, transport and logistics, as well as pharma that continue to hire.

Industrial Strength Samples has launched Pharmaceutical Movie Clips sample pack featuring a collection of vocal samples. The content provided has been sorted thru and does not contain any offensive samples that are directed to any one or any one group of people. It’s comical and pretty hardcore at the same time. Pharmaceutical Movie Clips offers […]

The post Industrial Strength releases Pharmaceutical Movie Clips sample pack appeared first on rekkerd.org.

Although warehouses are open and delivery staff moving freely, they are operating at suboptimal capacity. Since there is increased consumer demand, there is scarcity of medicines ordered online.

While most brick-and-mortar pharmacies continue to function amid the countrywide lockdown to contain the pandemic, many consumers have switched to buying medicines online for fear of getting infected by the novel coronavirus, industry insiders said.

Apart from Covid-19 lockdown norms, paucity of adequate stocks and a minuscule discount in retail medicine shops shot the demand for medicine delivery through various e-pharmacy platforms.

The conversations between Reliance and Netmeds, which had also held talks with Walmart-owned Flipkart, had been going on before the coronavirus lockdown, sources said.

SJM national co-convenor Ashwani Mahajan tweeted on this issue, tagging Prime Minister Narendra Modi, to flag his concern. . Mahajan had shared screenshots that said Aarogya Setu now brings to you online medical consultations (call and video), home lab tests and e-pharmacy.

On this edition of Your Call’s Media Roundtable, we're discussing the economic impact of the COVID-19 pandemic on Italy and other hard hit European countries. According to The European Commission, Europe’s economy will shrink by 7.4 percent this year.

Die Biotech-Branche steht derzeit wie nie zuvor in der Öffentlichkeit. Sie soll den Impfstoff gegen das Coronavirus erfinden. Doch auch schon bisher wurden in den Unternehmen hohe Gehälter gezahlt. In den Spitzenpositionen sind die Unterschiede jedoch extrem.

Shares of Avadel Pharmaceuticals plc (AVDL) are soaring over 37% in pre-market today, after the company announced positive topline data from its pivotal Phase 3 REST-ON trial assessing the safety and efficacy of FT218, an investigational, once-nightly formulation of sodium oxybate for the treatment of excessive daytime sleepiness and cataplexy in patients with narcolepsy.

Shares of CNS Pharmaceuticals Inc. (CNSP) are rising over 7% in pre-market today, after the company announced that it has filed an application with the U.S. FDA to receive Orphan Drug Designation or ODD for its lead product Berubicin.

Shares of Alexion Pharmaceuticals, Inc. (ALXN) are down more than 5 percent or $5.37 in Tuesday's morning trade at $98.47. The stock has traded in a range of $72.67 to $136.51 in the past 52 weeks.

An Australian medicinal cannabis company is working to address a global shortage of pharmaceutical-grade product, reducing cost and improving access at the same time.

With the global death toll now at more than 100,000, there is an urgent need for a coronavirus vaccine. But will pharmaceutical companies be tempted to put profits before patients?

A pharmaceutical giant owned by the Sackler family in the United States is using flaws in regulation to push its latest product deep into regional Australia.

A former Adelaide doctor jailed for trying to murder a pharmacistwho reported him for overprescribing medication loses his bid to reduce his decade-long sentence.

Investment in new warehouse storage and handling systems has helped an online pharmacy secure an estimated 30% improvement in productivity.

Investors in MEI Pharma, Inc. (NASDAQ:MEIP) had a good week, as its shares rose 3.8% to close at US$2.74 following the...

Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) investors will be delighted, with the company turning in some strong...

(United States Federal Circuit) - Affirmed the bench trial finding that valid patents still existed in a longstanding pharmaceutical drug called Aveed after defendant Custopharm was sued for patent infringement by Endo Pharmaceuticals and Bayer after seeking FDA approval to produce a generic version of Aveed.

(United States Federal Circuit) - Affirmed a finding of patent claim invalidity involving certain claims related to a drug distribution system for tracking prescriptions of sensitive drugs, such as those with addictive properties. In affirming, the Federal Circuit held that the Patent Trial and Appeal Board did not err and that its determination, on inter partes review, that the patents were invalid was obvious.

(United States Federal Circuit) - Affirmed that tribal sovereign immunity could not be asserted in a patent proceeding. A pharmaceutical company involved in a dispute over an eye medication patent transferred the title of its patent to a Native American tribe, which then moved to terminate the patent proceeding on the basis of sovereign immunity. Concluding that tribal sovereign immunity cannot be asserted in inter partes review, the Federal Circuit affirmed the denial of the Tribe's motion to terminate the proceeding.

(United States Supreme Court) - Held that an inventor's sale of an invention to a third party who is obligated to keep the invention confidential can qualify as prior art for purposes of determining the patentability of the invention. The dispute here involved two pharmaceutical companies that disagreed about whether a certain drug was under patent; one of the companies wanted to market a generic version of it. Justice Thomas delivered the unanimous opinion.

(United States Ninth Circuit) - 9th Circuit panel certified two questions to the California Supreme Court: 1) Does Section 16600 of the California Business and Professions Code apply to covenants not to compete not involving employer and employee? and 2) Does a claim for intentional interference with contractual relations require the plaintiff to plead and prove an intentionally wrongful act in cases not involving at-will employment contracts?

(United States Supreme Court) - Vacating and remanding the Second Circuit's support of a motion to dismiss a complaint relating to allegations that Chinese sellers of Vitamin C were engaged in price and quantity fixing of exports to the US because although the Ministry of Commerce of the People's Republic of China averred that the alleged price fixing scheme was actually a pricing regime mandated by the Chinese Government the court was not bound to accord conclusive effect to the foreign government's statements. No law or regulation had been cited and a foreign nation's laws must be proven as facts.

(California Court of Appeal) - Judgment for plaintiff in an action alleging intentional interference with a License Agreement, interference with plaintiff's prospective economic advantage, breach of a confidentiality agreement, and breach of confidence, arising out of defendant Actelion's notice to plaintiff that following its acquisition of defendant CoTherix, defendant Co-Therix's would discontinue development of plaintiff's drug for "business and commercial reasons," is affirmed, where: 1) defendant Actelion, by virtue of its ownership interest, is not automatically immune from tortious interference with the License Agreement; 2) the jury was properly instructed on the elements of wrongful interference with contract and properly charged with considering whether defendants "used unlawful means to interfere with the License Agreement;" and 3) the manager's privilege does not exempt a manager from liability when he or she tortiously interferes with a contract or relationship between third parties.

(United States Supreme Court) - Vacating and remanding the Second Circuit's support of a motion to dismiss a complaint relating to allegations that Chinese sellers of Vitamin C were engaged in price and quantity fixing of exports to the US because although the Ministry of Commerce of the People's Republic of China averred that the alleged price fixing scheme was actually a pricing regime mandated by the Chinese Government the court was not bound to accord conclusive effect to the foreign government's statements. No law or regulation had been cited and a foreign nation's laws must be proven as facts.

(United States Federal Circuit) - Affirmed the bench trial finding that valid patents still existed in a longstanding pharmaceutical drug called Aveed after defendant Custopharm was sued for patent infringement by Endo Pharmaceuticals and Bayer after seeking FDA approval to produce a generic version of Aveed.

(United States Federal Circuit) - Affirmed a finding of patent claim invalidity involving certain claims related to a drug distribution system for tracking prescriptions of sensitive drugs, such as those with addictive properties. In affirming, the Federal Circuit held that the Patent Trial and Appeal Board did not err and that its determination, on inter partes review, that the patents were invalid was obvious.

(United States Federal Circuit) - Affirmed that tribal sovereign immunity could not be asserted in a patent proceeding. A pharmaceutical company involved in a dispute over an eye medication patent transferred the title of its patent to a Native American tribe, which then moved to terminate the patent proceeding on the basis of sovereign immunity. Concluding that tribal sovereign immunity cannot be asserted in inter partes review, the Federal Circuit affirmed the denial of the Tribe's motion to terminate the proceeding.

(United States Supreme Court) - Held that an inventor's sale of an invention to a third party who is obligated to keep the invention confidential can qualify as prior art for purposes of determining the patentability of the invention. The dispute here involved two pharmaceutical companies that disagreed about whether a certain drug was under patent; one of the companies wanted to market a generic version of it. Justice Thomas delivered the unanimous opinion.

The Canadian Pharmacy Spammers are at it again, or should we say still at it again.

Stock market spammers are at it again. This time promoting the R.C.H.A stock.

(United States Federal Circuit) - In a patent infringement action, the district court's judgment for plaintiff Bayer is reversed where it clearly erred in determining that a skilled artisan would not have been motivated to create an oral disintegrating tablet version of an erectile dysfunction drug using specified sugar alcohols with the tablet formulated for immediate-release.

(Supreme Court of California) - Affirming the Court of Appeals determination that the manufacturer of a name brand drug whose labeling directs the warnings provided on its generic bioequivalent's packaging owes a duty of reasonable care to the consumers of the generic drug and that the liability for potential negligence doesn't automatically terminate upon transfer of the company's rights in the name brand drug to a successor manufacturer.

(United States Federal Circuit) - Affirming the District Court's determination that a proposed generic nasal spray would not infringe the patents of a company manufacturing the Nasonex nasal product.

(United States Ninth Circuit) - Partly affirming, partly vacating, and remanding the district court dismissal of a False Claims Act action brought against three pharmaceutical companies in a case involving off-label drug use and kickbacks to doctors because claims were substantially similar to those that had already been publicly disclosed, vacating to determine whether the situation qualified for the original source exception.

(United States Federal Circuit) - Affirming the decision of the district court holding, after a bench trial, that the asserted claims of a patent relating to the treatment of schizophrenia with iloperidone administered based on the genotype of the patient were infringed and not invalid.

(United States Federal Circuit) - Affirming that a chemical compound that mirrored a patented chemical compound was encompassed by the description that only portrayed one of the arrangements in the claim.

(United States Federal Circuit) - Vacating the Patent Trial and Appeal Board's dismissal of an interference claim for lack of standing and remanding for further proceedings because the description of a method for removing hair using nanoparticles to damage hair follicles was a sufficient written description under the Patent Act because although the description only gave optical density rather than particles per ml, this was enough of a disclosure to convey to those skilled in the art that the inventor had possession of the claimed subject matter.

(United States Federal Circuit) - Affirming the decision of the Patent Trial and Appeal Board in an inter partes review proceeding of patents relating to boron-containing small molecules used to treat fungal infections, holding that all of the claims of a patent owned by a company were unpatentable for obviousness.

(United States Federal Circuit) - Affirmed the bench trial finding that valid patents still existed in a longstanding pharmaceutical drug called Aveed after defendant Custopharm was sued for patent infringement by Endo Pharmaceuticals and Bayer after seeking FDA approval to produce a generic version of Aveed.